Skip to main content
Top
Published in: Current Treatment Options in Gastroenterology 4/2022

27-09-2022 | Constipation | Geriatrics (S Katz and A Afzali, Section Editors)

Constipation and Fecal Incontinence in the Elderly

Authors: Benjamin I. Richter, MD, Anthony F. Skryd, MD, Scott M. Smukalla, MD

Published in: Current Treatment Options in Gastroenterology | Issue 4/2022

Login to get access

Abstract 

Purpose of Review

To describe the epidemiology, classification, pathogenesis, clinical features, diagnostic modalities, and treatment options for primary constipation and fecal incontinence (FI) in older adults.

Recent Findings

Both constipation and FI are classified using the Rome IV criteria and require exclusion of secondary causes before a primary diagnosis can be made. Initial evaluation should include a thorough clinical history, review of medications, triaging need for colonoscopy, and a digital rectal examination. When initial evaluation of constipation is unrevealing, conservative management with dietary modification and laxative therapy should be pursued. If these measures are unsuccessful, then further testing is indicated, which may include anorectal manometry or imaging. Defecation disorders benefit from biofeedback in addition to laxative therapy. When FI is suspected on initial evaluation, anorectal manometry should be performed with additional studies dependent on the clinical scenario. Treatment of FI is multimodal and may include bowel training, dietary modification, anti-diarrheal agents, biofeedback therapy, and sacral nerve stimulation, among other interventions.

Summary

Constipation and fecal incontinence are common conditions in the elderly that have significant impact on quality of life. Both conditions require exclusion of secondary causes and a multi-modal approach to diagnostics and management.
Literature
1.
go back to reference Bharucha AE, Zinsmeister AR, Schleck CD, Melton LJ. Bowel disturbances are the most important risk factors for late onset fecal incontinence: a population-based case-control study in women. Gastroenterol WB Saunders. 2010;139:1559–66. Bharucha AE, Zinsmeister AR, Schleck CD, Melton LJ. Bowel disturbances are the most important risk factors for late onset fecal incontinence: a population-based case-control study in women. Gastroenterol WB Saunders. 2010;139:1559–66.
2.
go back to reference Bharucha AE, Zinsmeister AR, Locke GR, Seide BM, Mckeon K, Schleck CD, et al. Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterol WB Saunders. 2005;129:42–9. Bharucha AE, Zinsmeister AR, Locke GR, Seide BM, Mckeon K, Schleck CD, et al. Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterol WB Saunders. 2005;129:42–9.
4.
go back to reference Kunduru L, Kim SM, Heymen S, Whitehead WE. Factors that affect consultation and screening for fecal incontinence. Clin Gastroenterol Hepatol WB Saunders. 2015;13:709–16.CrossRef Kunduru L, Kim SM, Heymen S, Whitehead WE. Factors that affect consultation and screening for fecal incontinence. Clin Gastroenterol Hepatol WB Saunders. 2015;13:709–16.CrossRef
5.
go back to reference Miner PB. Economic and personal impact of fecal and urinary incontinence. Gastroenterol WB Saunders 2004;126. Miner PB. Economic and personal impact of fecal and urinary incontinence. Gastroenterol WB Saunders 2004;126.
6.
go back to reference Cotterill N, Norton C, Avery KNL, Abrams P, Donovan JL. A patient-centered approach to developing a comprehensive symptom and quality of life assessment of anal incontinence. Dis Colon Rectum. 2008;51:82–7.CrossRef Cotterill N, Norton C, Avery KNL, Abrams P, Donovan JL. A patient-centered approach to developing a comprehensive symptom and quality of life assessment of anal incontinence. Dis Colon Rectum. 2008;51:82–7.CrossRef
7.
go back to reference Whitehead WE, Drinkwater D, Cheskin LJ, Heller BR, Schuster MM. Constipation in the elderly living at home. J Am Geriatr Soc. 1989;37:423–9.CrossRef Whitehead WE, Drinkwater D, Cheskin LJ, Heller BR, Schuster MM. Constipation in the elderly living at home. J Am Geriatr Soc. 1989;37:423–9.CrossRef
8.
go back to reference Werth BL, Williams KA, Fisher MJ, Pont LG. Defining constipation to estimate its prevalence in the community: results from a national survey. BMC Gastroenterol BioMed Central Ltd 2019;19. Werth BL, Williams KA, Fisher MJ, Pont LG. Defining constipation to estimate its prevalence in the community: results from a national survey. BMC Gastroenterol BioMed Central Ltd 2019;19.
9.
go back to reference Ditah I, Devaki P, Luma HN, Ditah C, Njei B, Jaiyeoba C, et al. Prevalence, trends, and risk factors for fecal incontinence in United States Adults, 2005–2010. Clinical Gastroenterology and Hepatology. WB Saunders 2014;12. Ditah I, Devaki P, Luma HN, Ditah C, Njei B, Jaiyeoba C, et al. Prevalence, trends, and risk factors for fecal incontinence in United States Adults, 2005–2010. Clinical Gastroenterology and Hepatology. WB Saunders 2014;12.
10.
go back to reference Menees SB, Almario CV, Spiegel BMR, Chey WD. Prevalence of and factors associated with fecal incontinence: results from a population-based survey. Gastroenterol WB Saunders. 2018;154:1672–81 (e3).CrossRef Menees SB, Almario CV, Spiegel BMR, Chey WD. Prevalence of and factors associated with fecal incontinence: results from a population-based survey. Gastroenterol WB Saunders. 2018;154:1672–81 (e3).CrossRef
11.
go back to reference Mugie SM, Benninga MA, di Lorenzo C. Epidemiology of constipation in children and adults: a systematic review. Best Pract Res Clin Gastroenterol Bailliere Tindall Ltd. 2011;25:3–18.CrossRef Mugie SM, Benninga MA, di Lorenzo C. Epidemiology of constipation in children and adults: a systematic review. Best Pract Res Clin Gastroenterol Bailliere Tindall Ltd. 2011;25:3–18.CrossRef
12.
go back to reference Whitehead WE, Borrud L, Goode PS, Meikle S, Mueller ER, Tuteja A, et al. Fecal incontinence in us adults: epidemiology and risk factors. Gastroenterology. W.B. Saunders 2009;137. Whitehead WE, Borrud L, Goode PS, Meikle S, Mueller ER, Tuteja A, et al. Fecal incontinence in us adults: epidemiology and risk factors. Gastroenterology. W.B. Saunders 2009;137.
13.
go back to reference Kinnunen O. Study of constipation in a geriatric hospital, day hospital, old people’s home and at home. Aging (Milano). 1991;3:161–70. Kinnunen O. Study of constipation in a geriatric hospital, day hospital, old people’s home and at home. Aging (Milano). 1991;3:161–70.
14.
go back to reference Lämås K, Karlsson S, Nolén A, Lövheim H, Sandman P-O. Prevalence of constipation among persons living in institutional geriatric-care settings - a cross-sectional study. Scand J Caring Sci. 2017;31:157–63.CrossRef Lämås K, Karlsson S, Nolén A, Lövheim H, Sandman P-O. Prevalence of constipation among persons living in institutional geriatric-care settings - a cross-sectional study. Scand J Caring Sci. 2017;31:157–63.CrossRef
15.
go back to reference Nelson RL. Epidemiology of Fecal Incontinence. Gastroenterology. W.B. Saunders; 2004;126. Nelson RL. Epidemiology of Fecal Incontinence. Gastroenterology. W.B. Saunders; 2004;126.
16.
go back to reference Bouras E, Vazquez-Roque M. Epidemiology and management of chronic constipation in elderly patients. Clin Interv Aging. 2015;919. Bouras E, Vazquez-Roque M. Epidemiology and management of chronic constipation in elderly patients. Clin Interv Aging. 2015;919.
18.
go back to reference Noelting J, Eaton JE, Choung RS, Zinsmeister AR, Locke GR, Bharucha AE. The incidence rate and characteristics of clinically diagnosed defecatory disorders in the community. Neurogastroenterol Motil. 2016;28:1690–7.CrossRef Noelting J, Eaton JE, Choung RS, Zinsmeister AR, Locke GR, Bharucha AE. The incidence rate and characteristics of clinically diagnosed defecatory disorders in the community. Neurogastroenterol Motil. 2016;28:1690–7.CrossRef
19.
go back to reference Jamieson HA, Schluter PJ, Pyun J, Arnold T, Scrase R, Nisbet-Abey R, et al. Fecal incontinence is associated with mortality among older adults with complex needs: an observational cohort study. Am Jo Gastroenterol [Internet] Nature Publ Group. 2017;112:1431–7 (Available from: https://journals.lww.com/ajg/Fulltext/2017/09000/Fecal_Incontinence_Is_Associated_With_Mortality.19.aspx).CrossRef Jamieson HA, Schluter PJ, Pyun J, Arnold T, Scrase R, Nisbet-Abey R, et al. Fecal incontinence is associated with mortality among older adults with complex needs: an observational cohort study. Am Jo Gastroenterol [Internet] Nature Publ Group. 2017;112:1431–7 (Available from: https://​journals.​lww.​com/​ajg/​Fulltext/​2017/​09000/​Fecal_​Incontinence_​Is_​Associated_​With_​Mortality.​19.​aspx).CrossRef
20.
go back to reference Bharucha AE, Pemberton JH, Locke GR. American gastroenterological association technical review on constipation. Gastroenterol WB Saunders. 2013;144:218–38.CrossRef Bharucha AE, Pemberton JH, Locke GR. American gastroenterological association technical review on constipation. Gastroenterol WB Saunders. 2013;144:218–38.CrossRef
21.
go back to reference Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol. 2011;25(Suppl B):16B-21B.CrossRef Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol. 2011;25(Suppl B):16B-21B.CrossRef
22.
go back to reference Wong RK, Palsson OS, Turner MJ, Levy RL, Feld AD, von Korff M, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol. 2010;105:2228–34.CrossRef Wong RK, Palsson OS, Turner MJ, Levy RL, Feld AD, von Korff M, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol. 2010;105:2228–34.CrossRef
23.
go back to reference Rao SSC, Bharucha AE, Chiarioni G, Felt-Bersma R, Knowles C, Malcolm A, et al. Anorectal Disorders. Gastroenterology. 2016;150:1430-1442.e4.CrossRef Rao SSC, Bharucha AE, Chiarioni G, Felt-Bersma R, Knowles C, Malcolm A, et al. Anorectal Disorders. Gastroenterology. 2016;150:1430-1442.e4.CrossRef
24.
go back to reference Gladman MA, Lunniss PJ, Scott SM, Swash M. Rectal hyposensitivity. Am J Gastroenterol. 2006;101:1140–51.CrossRef Gladman MA, Lunniss PJ, Scott SM, Swash M. Rectal hyposensitivity. Am J Gastroenterol. 2006;101:1140–51.CrossRef
25.
go back to reference Mukhtar K, Nawaz H, Abid S. Functional gastrointestinal disorders and gut-brain axis: what does the future hold? World J Gastroenterol. 2019;25:552–66.CrossRef Mukhtar K, Nawaz H, Abid S. Functional gastrointestinal disorders and gut-brain axis: what does the future hold? World J Gastroenterol. 2019;25:552–66.CrossRef
26.
go back to reference Whitehead WE, di Lorenzo C, Leroi AM, Porrett T, Rao SS. Conservative and behavioural management of constipation. Neurogastroenterol Motil. 2009;21(Suppl 2):55–61.CrossRef Whitehead WE, di Lorenzo C, Leroi AM, Porrett T, Rao SS. Conservative and behavioural management of constipation. Neurogastroenterol Motil. 2009;21(Suppl 2):55–61.CrossRef
27.
go back to reference Preston DM, Lennard-Jones JE. Anismus in chronic constipation. Dig Dis Sci. 1985;30:413–8.CrossRef Preston DM, Lennard-Jones JE. Anismus in chronic constipation. Dig Dis Sci. 1985;30:413–8.CrossRef
28.
go back to reference Rao SS, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. Am J Gastroenterol. 1998;93:1042–50.CrossRef Rao SS, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. Am J Gastroenterol. 1998;93:1042–50.CrossRef
29.
go back to reference Rao SSC, Mudipalli RS, Stessman M, Zimmerman B. Investigation of the utility of colorectal function tests and Rome II criteria in dyssynergic defecation (Anismus). Neurogastroenterol Motil. 2004;16:589–96.CrossRef Rao SSC, Mudipalli RS, Stessman M, Zimmerman B. Investigation of the utility of colorectal function tests and Rome II criteria in dyssynergic defecation (Anismus). Neurogastroenterol Motil. 2004;16:589–96.CrossRef
30.
go back to reference Pasanen ME. Evaluation and treatment of colonic symptoms. Med Clin North Am. 2014;98:529–47.CrossRef Pasanen ME. Evaluation and treatment of colonic symptoms. Med Clin North Am. 2014;98:529–47.CrossRef
31.
go back to reference Ashraf W, Park F, Lof J, Quigley EM. An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation. Am J Gastroenterol. 1996;91:26–32. Ashraf W, Park F, Lof J, Quigley EM. An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation. Am J Gastroenterol. 1996;91:26–32.
32.
go back to reference Tantiphlachiva K, Rao P, Attaluri A, Rao SSC. Digital rectal examination is a useful tool for identifying patients with dyssynergia. Clin Gastroenterol Hepatol. 2010;8:955–60.CrossRef Tantiphlachiva K, Rao P, Attaluri A, Rao SSC. Digital rectal examination is a useful tool for identifying patients with dyssynergia. Clin Gastroenterol Hepatol. 2010;8:955–60.CrossRef
33.
go back to reference Bharucha AE, Lacy BE. Mechanisms, evaluation, and management of chronic constipation. Gastroenterology. 2020;158:1232-1249.e3. Recent, comprehensive review article on constipation.CrossRef Bharucha AE, Lacy BE. Mechanisms, evaluation, and management of chronic constipation. Gastroenterology. 2020;158:1232-1249.e3. Recent, comprehensive review article on constipation.CrossRef
34.
go back to reference Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol NLM (Medline). 2021;116:458–79.CrossRef Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol NLM (Medline). 2021;116:458–79.CrossRef
35.
go back to reference Rao SSC, Ozturk R, Laine L. Clinical utility of diagnostic tests for constipation in adults: a systematic review. Am J Gastroenterol. 2005;100:1605–15.CrossRef Rao SSC, Ozturk R, Laine L. Clinical utility of diagnostic tests for constipation in adults: a systematic review. Am J Gastroenterol. 2005;100:1605–15.CrossRef
36.
go back to reference Serra J, Pohl D, Azpiroz F, Chiarioni G, Ducrotté P, Gourcerol G, et al. European society of neurogastroenterology and motility guidelines on functional constipation in adults. Neurogastroenterology & Motility. 2020;32. European guidelines on management of constipation. Serra J, Pohl D, Azpiroz F, Chiarioni G, Ducrotté P, Gourcerol G, et al. European society of neurogastroenterology and motility guidelines on functional constipation in adults. Neurogastroenterology & Motility. 2020;32. European guidelines on management of constipation.
37.
go back to reference Rao SSC, Yu S, Fedewa A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41:1256–70.CrossRef Rao SSC, Yu S, Fedewa A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41:1256–70.CrossRef
38.
go back to reference Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther. 2011;33:895–901.CrossRef Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther. 2011;33:895–901.CrossRef
39.
go back to reference King DE, Mainous AG, Lambourne CA. Trends in dietary fiber intake in the United States, 1999–2008. J Acad Nutr Diet. 2012;112:642–8.CrossRef King DE, Mainous AG, Lambourne CA. Trends in dietary fiber intake in the United States, 1999–2008. J Acad Nutr Diet. 2012;112:642–8.CrossRef
40.
go back to reference Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349:1360–8.CrossRef Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349:1360–8.CrossRef
41.
go back to reference Bijkerk CJ, de Wit NJ, Muris JWM, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial BMJ. 2009;339:b3154–b3154. Bijkerk CJ, de Wit NJ, Muris JWM, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial BMJ. 2009;339:b3154–b3154.
42.
go back to reference Kang SJ, Cho YS, Lee TH, Kim S-E, Ryu HS, Kim J-W, et al. Medical management of constipation in elderly patients: systematic review. J Neurogastroenterol Motil. 2021;27:495–512. Recent, systematic review of constipation management specifically in the elderly.CrossRef Kang SJ, Cho YS, Lee TH, Kim S-E, Ryu HS, Kim J-W, et al. Medical management of constipation in elderly patients: systematic review. J Neurogastroenterol Motil. 2021;27:495–512. Recent, systematic review of constipation management specifically in the elderly.CrossRef
43.
go back to reference McRorie JW. Evidence-based approach to fiber supplements and clinically meaningful health benefits, Part 2. Nutr Today. 2015;50:90–7.CrossRef McRorie JW. Evidence-based approach to fiber supplements and clinically meaningful health benefits, Part 2. Nutr Today. 2015;50:90–7.CrossRef
44.
go back to reference DiPalma JA, Cleveland MVB, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436–41.CrossRef DiPalma JA, Cleveland MVB, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436–41.CrossRef
45.
go back to reference Paré P, Fedorak RN. Systematic review of stimulant and nonstimulant laxatives for the treatment of functional constipation. Can J Gastroenterol Hepatol. 2014;28:549–57.CrossRef Paré P, Fedorak RN. Systematic review of stimulant and nonstimulant laxatives for the treatment of functional constipation. Can J Gastroenterol Hepatol. 2014;28:549–57.CrossRef
46.
go back to reference Chassagne P, Ducrotte P, Garnier P, Mathiex-Fortunet H. Tolerance and long-term efficacy of polyethylene glycol 4000 (Forlax®) compared to lactulose in elderly patients with chronic constipation. J Nutr Health Aging. 2017;21:429–39.CrossRef Chassagne P, Ducrotte P, Garnier P, Mathiex-Fortunet H. Tolerance and long-term efficacy of polyethylene glycol 4000 (Forlax®) compared to lactulose in elderly patients with chronic constipation. J Nutr Health Aging. 2017;21:429–39.CrossRef
47.
go back to reference Rao SSC, Brenner DM. Efficacy and safety of over-the-counter therapies for chronic constipation: an updated systematic review. Am J Gastroenterol NLM (Medline). 2021;116:1156–81.CrossRef Rao SSC, Brenner DM. Efficacy and safety of over-the-counter therapies for chronic constipation: an updated systematic review. Am J Gastroenterol NLM (Medline). 2021;116:1156–81.CrossRef
48.
go back to reference Kamm MA, Mueller-Lissner S, Wald A, Richter E, Swallow R, Gessner U. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol. 2011;9:577–83.CrossRef Kamm MA, Mueller-Lissner S, Wald A, Richter E, Swallow R, Gessner U. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol. 2011;9:577–83.CrossRef
49.
go back to reference Mueller-Lissner S, Kamm MA, Wald A, Hinkel U, Koehler U, Richter E, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105:897–903.CrossRef Mueller-Lissner S, Kamm MA, Wald A, Hinkel U, Koehler U, Richter E, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105:897–903.CrossRef
50.
go back to reference Morishita D, Tomita T, Mori S, Kimura T, Oshima T, Fukui H, et al. Senna versus magnesium oxide for the treatment of chronic constipation: a randomized, placebo-controlled trial. Am J Gastroenterol. 2021;116:152–61.CrossRef Morishita D, Tomita T, Mori S, Kimura T, Oshima T, Fukui H, et al. Senna versus magnesium oxide for the treatment of chronic constipation: a randomized, placebo-controlled trial. Am J Gastroenterol. 2021;116:152–61.CrossRef
51.
go back to reference Zhong LLD, Cheng C, Kun W, Dai L, Hu D, Ning Z, et al. Efficacy of MaZiRenWan, a Chinese herbal medicine, in patients with functional constipation in a randomized controlled trial. Clin Gastroenterol Hepatol. 2019;17:1303-1310.e18.CrossRef Zhong LLD, Cheng C, Kun W, Dai L, Hu D, Ning Z, et al. Efficacy of MaZiRenWan, a Chinese herbal medicine, in patients with functional constipation in a randomized controlled trial. Clin Gastroenterol Hepatol. 2019;17:1303-1310.e18.CrossRef
52.
go back to reference Wald A. Is Chronic Use of Stimulant Laxatives Harmful to the Colon? 2003. Wald A. Is Chronic Use of Stimulant Laxatives Harmful to the Colon? 2003.
53.
go back to reference Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–7.CrossRef Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–7.CrossRef
54.
go back to reference Rao SSC, Lichtlen P, Habibi S. Effects of lubiprostone, an intestinal secretagogue, on electrolyte homeostasis in chronic idiopathic and opioid-induced constipation. J Clin Gastroenterol. 2021;55:512–9.CrossRef Rao SSC, Lichtlen P, Habibi S. Effects of lubiprostone, an intestinal secretagogue, on electrolyte homeostasis in chronic idiopathic and opioid-induced constipation. J Clin Gastroenterol. 2021;55:512–9.CrossRef
55.
go back to reference Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS, et al. Low-dose linaclotide (72 μg) for chronic idiopathic constipation: a 12-week, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2018;113:105–14.CrossRef Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS, et al. Low-dose linaclotide (72 μg) for chronic idiopathic constipation: a 12-week, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2018;113:105–14.CrossRef
56.
go back to reference Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Neurogastroenterol Motil. 2014;26:499–509.CrossRef Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Neurogastroenterol Motil. 2014;26:499–509.CrossRef
57.
go back to reference Ishigo T, Shimotsubo T, Takada R, Nakano K, Fujii S, Kitagawa M, et al. Efficacy and safety of linaclotide in elderly patients. Yakugaku Zasshi. 2021;141:255–62.CrossRef Ishigo T, Shimotsubo T, Takada R, Nakano K, Fujii S, Kitagawa M, et al. Efficacy and safety of linaclotide in elderly patients. Yakugaku Zasshi. 2021;141:255–62.CrossRef
58.
go back to reference Nee JW, Johnston JM, Shea EP, Walls CE, Tripp K, Shiff S, et al. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis. Expert Rev Gastroenterol Hepatol. 2019;13:397–406.CrossRef Nee JW, Johnston JM, Shea EP, Walls CE, Tripp K, Shiff S, et al. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis. Expert Rev Gastroenterol Hepatol. 2019;13:397–406.CrossRef
59.
go back to reference Miner PB, Koltun WD, Wiener GJ, de La Portilla M, Prieto B, Shailubhai K, et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017;112:613–21.CrossRef Miner PB, Koltun WD, Wiener GJ, de La Portilla M, Prieto B, Shailubhai K, et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017;112:613–21.CrossRef
60.
go back to reference DeMicco M, Barrow L, Hickey B, Shailubhai K, Griffin P. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2017;10:837–51.CrossRef DeMicco M, Barrow L, Hickey B, Shailubhai K, Griffin P. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2017;10:837–51.CrossRef
61.
go back to reference Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2006;130:34–43.CrossRef Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2006;130:34–43.CrossRef
62.
go back to reference Niewinna K, Zielińska A, Fichna J. Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome. Expert Opin Pharmacother. 2020;21:73–84.CrossRef Niewinna K, Zielińska A, Fichna J. Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome. Expert Opin Pharmacother. 2020;21:73–84.CrossRef
63.
go back to reference Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–54.CrossRef Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–54.CrossRef
64.
go back to reference Emmanuel A, Mattace-Raso F, Neri MC, Petersen K-U, Rey E, Rogers J. Constipation in older people: a consensus statement. Int J Clin Pract. 2017;71:e12920.CrossRef Emmanuel A, Mattace-Raso F, Neri MC, Petersen K-U, Rey E, Rogers J. Constipation in older people: a consensus statement. Int J Clin Pract. 2017;71:e12920.CrossRef
65.
go back to reference Bharucha AE, Pemberton JH, Locke GR. American gastroenterological association technical review on constipation. Gastroenterology. 2013;144:218–38.CrossRef Bharucha AE, Pemberton JH, Locke GR. American gastroenterological association technical review on constipation. Gastroenterology. 2013;144:218–38.CrossRef
66.
go back to reference Minguez M, Herreros B, Sanchiz V, Hernandez V, Almela P, Añon R, et al. Predictive value of the balloon expulsion test for excluding the diagnosis of pelvic floor dyssynergia in constipation. Gastroenterology. 2004;126:57–62.CrossRef Minguez M, Herreros B, Sanchiz V, Hernandez V, Almela P, Añon R, et al. Predictive value of the balloon expulsion test for excluding the diagnosis of pelvic floor dyssynergia in constipation. Gastroenterology. 2004;126:57–62.CrossRef
67.
go back to reference Gosling J, Plumb A, Taylor SA, Cohen R, Emmanuel AV. High-resolution anal manometry: repeatability, validation, and comparison with conventional manometry. Neurogastroenterol Motil. 2019;31:e13591.CrossRef Gosling J, Plumb A, Taylor SA, Cohen R, Emmanuel AV. High-resolution anal manometry: repeatability, validation, and comparison with conventional manometry. Neurogastroenterol Motil. 2019;31:e13591.CrossRef
68.
go back to reference Basilisco G, Bharucha AE. High-resolution anorectal manometry: an expensive hobby or worth every penny? Neurogastroenterol Motil. 2017;29:e13125.CrossRef Basilisco G, Bharucha AE. High-resolution anorectal manometry: an expensive hobby or worth every penny? Neurogastroenterol Motil. 2017;29:e13125.CrossRef
69.
go back to reference Camilleri M, Ford AC, Mawe GM, Dinning PG, Rao SS, Chey WD, et al. Chronic constipation. Nat Rev Dis Primers. 2017;3:17095.CrossRef Camilleri M, Ford AC, Mawe GM, Dinning PG, Rao SS, Chey WD, et al. Chronic constipation. Nat Rev Dis Primers. 2017;3:17095.CrossRef
70.
go back to reference Basilisco G, Coletta M. Chronic constipation: A critical review. Dig Liver Dis. 2013;45:886–93.CrossRef Basilisco G, Coletta M. Chronic constipation: A critical review. Dig Liver Dis. 2013;45:886–93.CrossRef
71.
go back to reference Sharma A, Rao SSC, Kearns K, Orleck KD, Waldman SA. Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders. Aliment Pharmacol Ther. 2021;53:1250–67.CrossRef Sharma A, Rao SSC, Kearns K, Orleck KD, Waldman SA. Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders. Aliment Pharmacol Ther. 2021;53:1250–67.CrossRef
72.
go back to reference Grossi U, di Tanna GL, Heinrich H, Taylor SA, Knowles CH, Scott SM. Letter: limitations of defecography among patients with refractory constipation. Authors’ reply Aliment Pharmacol Ther. 2019;50:112–3.CrossRef Grossi U, di Tanna GL, Heinrich H, Taylor SA, Knowles CH, Scott SM. Letter: limitations of defecography among patients with refractory constipation. Authors’ reply Aliment Pharmacol Ther. 2019;50:112–3.CrossRef
73.
go back to reference Grossi U, di Tanna GL, Heinrich H, Taylor SA, Knowles CH, Scott SM. Systematic review with meta-analysis: defecography should be a first-line diagnostic modality in patients with refractory constipation. Aliment Pharmacol Ther. 2018;48:1186–201.CrossRef Grossi U, di Tanna GL, Heinrich H, Taylor SA, Knowles CH, Scott SM. Systematic review with meta-analysis: defecography should be a first-line diagnostic modality in patients with refractory constipation. Aliment Pharmacol Ther. 2018;48:1186–201.CrossRef
74.
go back to reference Basilisco G, Corsetti M. Letter: limitations of defecography among patients with refractory constipation. Aliment Pharmacol Ther. 2019;50:111–2.CrossRef Basilisco G, Corsetti M. Letter: limitations of defecography among patients with refractory constipation. Aliment Pharmacol Ther. 2019;50:111–2.CrossRef
75.
go back to reference Narayanan SP, Bharucha AE. A practical guide to biofeedback therapy for pelvic floor disorders. Curr Gastroenterol Rep. 2019;21:21.CrossRef Narayanan SP, Bharucha AE. A practical guide to biofeedback therapy for pelvic floor disorders. Curr Gastroenterol Rep. 2019;21:21.CrossRef
76.
go back to reference Rao SSC, Benninga MA, Bharucha AE, Chiarioni G, di Lorenzo C, Whitehead WE. ANMS-ESNM position paper and consensus guidelines on biofeedback therapy for anorectal disorders. Neurogastroenterol Motil. 2015;27:594–609.CrossRef Rao SSC, Benninga MA, Bharucha AE, Chiarioni G, di Lorenzo C, Whitehead WE. ANMS-ESNM position paper and consensus guidelines on biofeedback therapy for anorectal disorders. Neurogastroenterol Motil. 2015;27:594–609.CrossRef
77.
go back to reference Rao SSC, Seaton K, Miller M, Brown K, Nygaard I, Stumbo P, et al. randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol. 2007;5:331–8.CrossRef Rao SSC, Seaton K, Miller M, Brown K, Nygaard I, Stumbo P, et al. randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol. 2007;5:331–8.CrossRef
78.
go back to reference Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology. 2006;130:657–64.CrossRef Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology. 2006;130:657–64.CrossRef
79.
go back to reference Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum. 2007;50:428–41.CrossRef Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum. 2007;50:428–41.CrossRef
80.
go back to reference Farid M, el Monem HA, Omar W, el Nakeeb A, Fikry A, Youssef T, et al. Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients. Int J Colorectal Dis. 2009;24:115–20.CrossRef Farid M, el Monem HA, Omar W, el Nakeeb A, Fikry A, Youssef T, et al. Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients. Int J Colorectal Dis. 2009;24:115–20.CrossRef
81.
go back to reference Faried M, el Nakeeb A, Youssef M, Omar W, el Monem HA. Comparative study between surgical and non-surgical treatment of anismus in patients with symptoms of obstructed defecation: a prospective randomized study. J Gastrointest Surg. 2010;14:1235–43.CrossRef Faried M, el Nakeeb A, Youssef M, Omar W, el Monem HA. Comparative study between surgical and non-surgical treatment of anismus in patients with symptoms of obstructed defecation: a prospective randomized study. J Gastrointest Surg. 2010;14:1235–43.CrossRef
82.
go back to reference Rao SSC, Go JT, Valestin J, Schneider J. Home biofeedback for the treatment of dyssynergic defecation: does it improve quality of life and is it cost-effective? Am J Gastroenterol. 2019;114:938–44.CrossRef Rao SSC, Go JT, Valestin J, Schneider J. Home biofeedback for the treatment of dyssynergic defecation: does it improve quality of life and is it cost-effective? Am J Gastroenterol. 2019;114:938–44.CrossRef
83.
go back to reference Bharucha AE, Lacy BE. Mechanisms, Evaluation, and Management of Chronic Constipation. Gastroenterology. W.B. Saunders; 2020; 1232–1249.e3. Bharucha AE, Lacy BE. Mechanisms, Evaluation, and Management of Chronic Constipation. Gastroenterology. W.B. Saunders; 2020; 1232–1249.e3.
84.
go back to reference Staller K, Barshop K, Ananthakrishnan AN, Kuo B. Rectosigmoid localization of radiopaque markers does not correlate with prolonged balloon expulsion in chronic constipation: results from a multicenter cohort. Am J Gastroenterol. 2015;110:1049–55.CrossRef Staller K, Barshop K, Ananthakrishnan AN, Kuo B. Rectosigmoid localization of radiopaque markers does not correlate with prolonged balloon expulsion in chronic constipation: results from a multicenter cohort. Am J Gastroenterol. 2015;110:1049–55.CrossRef
85.
go back to reference Rao SSC, Kuo B, McCallum RW, Chey WD, DiBaise JK, Hasler WL, et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol. 2009;7:537–44.CrossRef Rao SSC, Kuo B, McCallum RW, Chey WD, DiBaise JK, Hasler WL, et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol. 2009;7:537–44.CrossRef
86.
go back to reference Hasler WL, Saad RJ, Rao SS, Wilding GE, Parkman HP, Koch KL, et al. Heightened colon motor activity measured by a wireless capsule in patients with constipation: relation to colon transit and IBS. Am J Physiol Gastrointest Liver Physiol. 2009;297:G1107–14.CrossRef Hasler WL, Saad RJ, Rao SS, Wilding GE, Parkman HP, Koch KL, et al. Heightened colon motor activity measured by a wireless capsule in patients with constipation: relation to colon transit and IBS. Am J Physiol Gastrointest Liver Physiol. 2009;297:G1107–14.CrossRef
87.
go back to reference Singh S, Heady S, Coss-Adame E, Rao SSC. Clinical utility of colonic manometry in slow transit constipation. Neurogastroenterol Motil. 2013;25:487-e367.CrossRef Singh S, Heady S, Coss-Adame E, Rao SSC. Clinical utility of colonic manometry in slow transit constipation. Neurogastroenterol Motil. 2013;25:487-e367.CrossRef
88.
go back to reference Hussain ZH, Everhart K, Lacy BE. Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies. Gastroenterol Hepatol (N Y). 2015;11:104–14. Hussain ZH, Everhart K, Lacy BE. Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies. Gastroenterol Hepatol (N Y). 2015;11:104–14.
89.
go back to reference Whitehead WE, Simren M, Busby-Whitehead J, Heymen S, van Tilburg MAL, Sperber AD, et al. Fecal incontinence diagnosed by the Rome IV Criteria in the United States, Canada, and the United Kingdom. Clin Gastroenterol Hepatol WB Saunders. 2020;18:385–91. Fecal incontinence prevalence and risk factors using Rome IV criteria.CrossRef Whitehead WE, Simren M, Busby-Whitehead J, Heymen S, van Tilburg MAL, Sperber AD, et al. Fecal incontinence diagnosed by the Rome IV Criteria in the United States, Canada, and the United Kingdom. Clin Gastroenterol Hepatol WB Saunders. 2020;18:385–91. Fecal incontinence prevalence and risk factors using Rome IV criteria.CrossRef
90.
go back to reference Bharucha AE. Pelvic floor: anatomy and function. Neurogastroenterol Motil. 2006;18:507–19.CrossRef Bharucha AE. Pelvic floor: anatomy and function. Neurogastroenterol Motil. 2006;18:507–19.CrossRef
91.
go back to reference Bharucha AE. High amplitude propagated contractions. Neurogastroenterol Motil. 2012;24:977–82.CrossRef Bharucha AE. High amplitude propagated contractions. Neurogastroenterol Motil. 2012;24:977–82.CrossRef
92.
go back to reference Rao SSC, Bharucha AE, Chiarioni G, Felt-Bersma R, Knowles C, Malcolm A, et al. Anorectal disorders. Gastroenterol WB Saunders. 2016;150:1430–42 (e4).CrossRef Rao SSC, Bharucha AE, Chiarioni G, Felt-Bersma R, Knowles C, Malcolm A, et al. Anorectal disorders. Gastroenterol WB Saunders. 2016;150:1430–42 (e4).CrossRef
93.
go back to reference Fox JC, Fletcher JG, Zinsmeister AR, Seide B, Riederer SJ, Bharucha AE. Effect of aging on anorectal and pelvic floor functions in females. Dis Colon Rectum. 2006;49:1726–35.CrossRef Fox JC, Fletcher JG, Zinsmeister AR, Seide B, Riederer SJ, Bharucha AE. Effect of aging on anorectal and pelvic floor functions in females. Dis Colon Rectum. 2006;49:1726–35.CrossRef
94.
go back to reference Melville JL, Fan MY, Newton K, Fenner D. Fecal incontinence in US women: a population-based study. Am J Obstet Gynecol. 2005;193:2071–6.CrossRef Melville JL, Fan MY, Newton K, Fenner D. Fecal incontinence in US women: a population-based study. Am J Obstet Gynecol. 2005;193:2071–6.CrossRef
95.
go back to reference Bharucha AE, Zinsmeister AR, Schleck CD, Melton LJ. Bowel disturbances are the most important risk factors for late onset fecal incontinence: a population-based case-control study in women. Gastroenterol WB Saunders. 2010;139:1559–66.CrossRef Bharucha AE, Zinsmeister AR, Schleck CD, Melton LJ. Bowel disturbances are the most important risk factors for late onset fecal incontinence: a population-based case-control study in women. Gastroenterol WB Saunders. 2010;139:1559–66.CrossRef
96.
go back to reference Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800–3.CrossRef Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800–3.CrossRef
97.
go back to reference Azpiroz F, Enck P, Whitehead WE. Anorectal functional testing: review of collective experience1. Am J Gastroenterol Ovid Technologies (Wolters Kluwer Health). 2002;97:232–40. Azpiroz F, Enck P, Whitehead WE. Anorectal functional testing: review of collective experience1. Am J Gastroenterol Ovid Technologies (Wolters Kluwer Health). 2002;97:232–40.
98.
go back to reference Bharucha AE, Zinsmeister AR, Locke GR, Seide BM, McKeon K, Schleck CD, et al. Risk factors for fecal incontinence: a population-based study in women. Am J Gastroenterol. 2006;101:1305–12.CrossRef Bharucha AE, Zinsmeister AR, Locke GR, Seide BM, McKeon K, Schleck CD, et al. Risk factors for fecal incontinence: a population-based study in women. Am J Gastroenterol. 2006;101:1305–12.CrossRef
99.
go back to reference Gu P, Kuenzig ME, Kaplan GG, Pimentel M, Rezaie A. Fecal Incontinence in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2018;24:1280–90.CrossRef Gu P, Kuenzig ME, Kaplan GG, Pimentel M, Rezaie A. Fecal Incontinence in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2018;24:1280–90.CrossRef
100.
go back to reference Garland CF, Lilienfeld AM, Mendeloff AI, Markowitz JA, Terrell KB, Garland FC. Incidence rates of ulcerative colitis and Crohn’s disease in fifteen areas of the United States. Gastroenterology. 1981;81:1115–24.CrossRef Garland CF, Lilienfeld AM, Mendeloff AI, Markowitz JA, Terrell KB, Garland FC. Incidence rates of ulcerative colitis and Crohn’s disease in fifteen areas of the United States. Gastroenterology. 1981;81:1115–24.CrossRef
101.
go back to reference Kamal N, Motwani K, Wellington J, Wong U, Cross RK. Fecal Incontinence in Inflammatory Bowel Disease. Crohns ColitiS 360. 2021;3:otab013.CrossRef Kamal N, Motwani K, Wellington J, Wong U, Cross RK. Fecal Incontinence in Inflammatory Bowel Disease. Crohns ColitiS 360. 2021;3:otab013.CrossRef
102.
go back to reference Varma MG, Brown JS, Creasman JM, Thom DH, van den Eeden SK, Beattie MS, et al. Fecal incontinence in females older than aged 40 years: who is at risk? Dis Colon Rectum. 2006;49:841–51.CrossRef Varma MG, Brown JS, Creasman JM, Thom DH, van den Eeden SK, Beattie MS, et al. Fecal incontinence in females older than aged 40 years: who is at risk? Dis Colon Rectum. 2006;49:841–51.CrossRef
103.
go back to reference Townsend MK, Matthews CA, Whitehead WE, Grodstein F. Risk factors for fecal incontinence in older women. Am J Gastroenterol. 2013;108:113–9.CrossRef Townsend MK, Matthews CA, Whitehead WE, Grodstein F. Risk factors for fecal incontinence in older women. Am J Gastroenterol. 2013;108:113–9.CrossRef
104.
go back to reference Staller K, Song M, Grodstein F, Whitehead WE, Matthews CA, Kuo B, et al. Increased Long-term Dietary Fiber Intake Is Associated With a Decreased Risk of Fecal Incontinence in Older Women. Gastroenterol WB Saunders. 2018;155:661–7 (e1).CrossRef Staller K, Song M, Grodstein F, Whitehead WE, Matthews CA, Kuo B, et al. Increased Long-term Dietary Fiber Intake Is Associated With a Decreased Risk of Fecal Incontinence in Older Women. Gastroenterol WB Saunders. 2018;155:661–7 (e1).CrossRef
105.
go back to reference Staller K, Song M, Grodstein F, Matthews CA, Whitehead WE, Kuo B, et al. Clinical and translational gastroenterology physical activity, BMI, and risk of fecal incontinence in the nurses’ health study. Clin Transl Gastroenterol. 2018;9:200.CrossRef Staller K, Song M, Grodstein F, Matthews CA, Whitehead WE, Kuo B, et al. Clinical and translational gastroenterology physical activity, BMI, and risk of fecal incontinence in the nurses’ health study. Clin Transl Gastroenterol. 2018;9:200.CrossRef
106.
go back to reference Markland AD, Dunivan GC, Vaughan CP, Rogers RG. Anal intercourse and fecal incontinence: evidence from the 2009–2010 National Health and Nutrition Examination Survey. Am J Gastroenterol. 2016;111:269–74.CrossRef Markland AD, Dunivan GC, Vaughan CP, Rogers RG. Anal intercourse and fecal incontinence: evidence from the 2009–2010 National Health and Nutrition Examination Survey. Am J Gastroenterol. 2016;111:269–74.CrossRef
107.
go back to reference Madoff RD, Parker SC, Varma MG, Lowry AC. Faecal incontinence in adults. Lancet Elsevier BV. 2004;364:621–32.CrossRef Madoff RD, Parker SC, Varma MG, Lowry AC. Faecal incontinence in adults. Lancet Elsevier BV. 2004;364:621–32.CrossRef
108.
go back to reference Nelson R, Norton N, Cautley E, Furner S. Community-based prevalence of anal incontinence. JAMA. 1995;274:559–61.CrossRef Nelson R, Norton N, Cautley E, Furner S. Community-based prevalence of anal incontinence. JAMA. 1995;274:559–61.CrossRef
109.
go back to reference Whitehead WE, Borrud L, Goode PS, Meikle S, Mueller ER, Tuteja A, et al. Fecal Incontinence in US Adults: Epidemiology and Risk Factors. Gastroenterology. W.B. Saunders; 2009;137. Whitehead WE, Borrud L, Goode PS, Meikle S, Mueller ER, Tuteja A, et al. Fecal Incontinence in US Adults: Epidemiology and Risk Factors. Gastroenterology. W.B. Saunders; 2009;137.
110.
go back to reference Gunterberg B, Kewenter J, Petersén I, Stener B. Anorectal function after major resections of the sacrum with bilateral or unilateral sacrifice of sacral nerves. Br J Surg. 1976;63:546–54.CrossRef Gunterberg B, Kewenter J, Petersén I, Stener B. Anorectal function after major resections of the sacrum with bilateral or unilateral sacrifice of sacral nerves. Br J Surg. 1976;63:546–54.CrossRef
111.
go back to reference Caruana BJ, Wald A, Hinds JP, Eidelman BH. Anorectal sensory and motor function in neurogenic fecal incontinence: comparison between multiple sclerosis and diabetes mellitus. Gastroenterol WB Saunders. 1991;100:465–70.CrossRef Caruana BJ, Wald A, Hinds JP, Eidelman BH. Anorectal sensory and motor function in neurogenic fecal incontinence: comparison between multiple sclerosis and diabetes mellitus. Gastroenterol WB Saunders. 1991;100:465–70.CrossRef
112.
go back to reference Swash M, Snooks SJ, Chalmers DH. Parity as a factor in incontinence in multiple sclerosis. Arch Neurol. 1987;44:504–8.CrossRef Swash M, Snooks SJ, Chalmers DH. Parity as a factor in incontinence in multiple sclerosis. Arch Neurol. 1987;44:504–8.CrossRef
113.
go back to reference Saga S, Vinsnes AG, Mørkved S, Norton C, Seim A. Prevalence and correlates of fecal incontinence among nursing home residents: a population-based cross-sectional study. BMC Geriatr. 2013;13:87.CrossRef Saga S, Vinsnes AG, Mørkved S, Norton C, Seim A. Prevalence and correlates of fecal incontinence among nursing home residents: a population-based cross-sectional study. BMC Geriatr. 2013;13:87.CrossRef
114.
go back to reference Bickley L, Szilagyi. Chapter 15: The anus, rectum, and prostate. bates’ guide to physical examination and history taking. 11e ed. Lippincott Williams & Wilkins; 2013. Bickley L, Szilagyi. Chapter 15: The anus, rectum, and prostate. bates’ guide to physical examination and history taking. 11e ed. Lippincott Williams & Wilkins; 2013.
115.
go back to reference Talley NJ. How to do and interpret a rectal examination in gastroenterology. Am J Gastroenterol. 2008;103:820–2.CrossRef Talley NJ. How to do and interpret a rectal examination in gastroenterology. Am J Gastroenterol. 2008;103:820–2.CrossRef
116.
go back to reference Chassagne P, Landrin I, Neveu C, Czernichow P, Bouaniche M, Doucet J, et al. Fecal incontinence in the institutionalized elderly: Incidence, risk factors, and prognosis. Am J Med. 1999;106:185–90.CrossRef Chassagne P, Landrin I, Neveu C, Czernichow P, Bouaniche M, Doucet J, et al. Fecal incontinence in the institutionalized elderly: Incidence, risk factors, and prognosis. Am J Med. 1999;106:185–90.CrossRef
117.
go back to reference Hancke E, Schiirholz M. Col6~ Disease Impaired rectal sensation in idiopathic faecal incontinence. Int J Colorect Dis. 1987. Hancke E, Schiirholz M. Col6~ Disease Impaired rectal sensation in idiopathic faecal incontinence. Int J Colorect Dis. 1987.
118.
go back to reference Dobben AC, Terra MP, Deutekom M, Gerhards MF, Bijnen AB, Felt-Bersma RJF, et al. Anal inspection and digital rectal examination compared to anorectal physiology tests and endoanal ultrasonography in evaluating fecal incontinence. Int J Colorectal Dis. 2007;22:783–90.CrossRef Dobben AC, Terra MP, Deutekom M, Gerhards MF, Bijnen AB, Felt-Bersma RJF, et al. Anal inspection and digital rectal examination compared to anorectal physiology tests and endoanal ultrasonography in evaluating fecal incontinence. Int J Colorectal Dis. 2007;22:783–90.CrossRef
119.
go back to reference Lee TH, Bharucha AE. How to Perform and Interpret a High-resolution Anorectal Manometry Test. J Neurogastroenterol Motil. 2016;22:46–59.CrossRef Lee TH, Bharucha AE. How to Perform and Interpret a High-resolution Anorectal Manometry Test. J Neurogastroenterol Motil. 2016;22:46–59.CrossRef
120.
go back to reference Meyer I, Richter HE. An evidence-based approach to the evaluation, diagnostic assessment and treatment of fecal incontinence in women. Curr Obstet Gynecol Rep. 2014;3:155–64.CrossRef Meyer I, Richter HE. An evidence-based approach to the evaluation, diagnostic assessment and treatment of fecal incontinence in women. Curr Obstet Gynecol Rep. 2014;3:155–64.CrossRef
121.
go back to reference Hiltunen K-M, Kolehmainen H, Matikainen M. Does defecography help in diagnosis and clinical decision-making in defecation disorders? Abdom Imaging. 1994. Hiltunen K-M, Kolehmainen H, Matikainen M. Does defecography help in diagnosis and clinical decision-making in defecation disorders? Abdom Imaging. 1994.
122.
go back to reference Rao S. Diagnosis and management of fecal incontinence. Am J Gastroenterol. 2004;99:1585–604.CrossRef Rao S. Diagnosis and management of fecal incontinence. Am J Gastroenterol. 2004;99:1585–604.CrossRef
123.
go back to reference Wald A. Clinical practice. Fecal incontinence in adults. N Engl J Med. 2007;356:1648–55.CrossRef Wald A. Clinical practice. Fecal incontinence in adults. N Engl J Med. 2007;356:1648–55.CrossRef
124.
go back to reference Fader M, Cottenden AM, Getliffe K. Absorbent products for moderate-heavy urinary and/or faecal incontinence in women and men. Cochrane Database Syst Rev. 2008;CD007408. Fader M, Cottenden AM, Getliffe K. Absorbent products for moderate-heavy urinary and/or faecal incontinence in women and men. Cochrane Database Syst Rev. 2008;CD007408.
125.
go back to reference Markland AD, Burgio KL, Whitehead WE, Richter HE, Wilcox CM, Redden DT, et al. Loperamide Versus Psyllium Fiber for Treatment of fecal incontinence: the fecal incontinence prescription (Rx) management (FIRM) randomized clinical trial. Dis Colon Rectum. 2015;58:983–93.CrossRef Markland AD, Burgio KL, Whitehead WE, Richter HE, Wilcox CM, Redden DT, et al. Loperamide Versus Psyllium Fiber for Treatment of fecal incontinence: the fecal incontinence prescription (Rx) management (FIRM) randomized clinical trial. Dis Colon Rectum. 2015;58:983–93.CrossRef
126.
go back to reference Shee CD, Pounder RE. Loperamide, diphenoxylate, and codeine phosphate in chronic diarrhoea. Br Med J. 1980;280:524.CrossRef Shee CD, Pounder RE. Loperamide, diphenoxylate, and codeine phosphate in chronic diarrhoea. Br Med J. 1980;280:524.CrossRef
127.
go back to reference Read M, Read NW, Barber DC, Duthie HL. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci. 1982;27:807–14.CrossRef Read M, Read NW, Barber DC, Duthie HL. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci. 1982;27:807–14.CrossRef
128.
go back to reference Sun WM, Read NW, Verlinden M. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol. 1997;32:34–8.CrossRef Sun WM, Read NW, Verlinden M. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol. 1997;32:34–8.CrossRef
129.
go back to reference Cheung O, Wald A. Review article: the management of pelvic floor disorders. Aliment Pharmacol Ther. 2004;19:481–95.CrossRef Cheung O, Wald A. Review article: the management of pelvic floor disorders. Aliment Pharmacol Ther. 2004;19:481–95.CrossRef
130.
go back to reference Lowery SP, Srour JW, Whitehead WE, Schuster MM. Habit training as treatment of encopresis secondary to chronic constipation. J Pediatr Gastroenterol Nutr. 1985;4:397–401.CrossRef Lowery SP, Srour JW, Whitehead WE, Schuster MM. Habit training as treatment of encopresis secondary to chronic constipation. J Pediatr Gastroenterol Nutr. 1985;4:397–401.CrossRef
131.
go back to reference Rao SS. The technical aspects of biofeedback therapy for defecation disorders. Gastroenterologist. 1998;6:96–103. Rao SS. The technical aspects of biofeedback therapy for defecation disorders. Gastroenterologist. 1998;6:96–103.
132.
go back to reference Mazor Y, Ejova A, Andrews A, Jones M, Kellow J, Malcolm A. Long-term outcome of anorectal biofeedback for treatment of fecal incontinence. Neurogastroenterol Motil. 2018;e13389. Mazor Y, Ejova A, Andrews A, Jones M, Kellow J, Malcolm A. Long-term outcome of anorectal biofeedback for treatment of fecal incontinence. Neurogastroenterol Motil. 2018;e13389.
133.
go back to reference Sjödahl J, Walter SA, Johansson E, Ingemansson A, Ryn A-K, Hallböök O. Combination therapy with biofeedback, loperamide, and stool-bulking agents is effective for the treatment of fecal incontinence in women - a randomized controlled trial. Scand J Gastroenterol. 2015;50:965–74.CrossRef Sjödahl J, Walter SA, Johansson E, Ingemansson A, Ryn A-K, Hallböök O. Combination therapy with biofeedback, loperamide, and stool-bulking agents is effective for the treatment of fecal incontinence in women - a randomized controlled trial. Scand J Gastroenterol. 2015;50:965–74.CrossRef
134.
go back to reference Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, Madoff RD, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56:234–45.CrossRef Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, Madoff RD, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56:234–45.CrossRef
135.
go back to reference Leroi AM, Michot F, Grise P, Denis P. Effect of sacral nerve stimulation in patients with fecal and urinary incontinence. Dis Colon Rectum. 2001;44:779–89.CrossRef Leroi AM, Michot F, Grise P, Denis P. Effect of sacral nerve stimulation in patients with fecal and urinary incontinence. Dis Colon Rectum. 2001;44:779–89.CrossRef
136.
go back to reference Wexner SD, Coller JA, Devroede G, Hull T, McCallum R, Chan M, et al. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. Ann Surg. 2010;251:441–9.CrossRef Wexner SD, Coller JA, Devroede G, Hull T, McCallum R, Chan M, et al. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. Ann Surg. 2010;251:441–9.CrossRef
137.
go back to reference Thaha MA, Abukar AA, Thin NN, Ramsanahie A, Knowles CH. Sacral nerve stimulation for faecal incontinence and constipation in adults. Cochrane Database Syst Rev. 2015;CD004464. Thaha MA, Abukar AA, Thin NN, Ramsanahie A, Knowles CH. Sacral nerve stimulation for faecal incontinence and constipation in adults. Cochrane Database Syst Rev. 2015;CD004464.
138.
go back to reference Knowles CH, Horrocks EJ, Bremner SA, Stevens N, Norton C, O’Connell PR, et al. Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial. Lancet. 2015;386:1640–8.CrossRef Knowles CH, Horrocks EJ, Bremner SA, Stevens N, Norton C, O’Connell PR, et al. Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial. Lancet. 2015;386:1640–8.CrossRef
139.
go back to reference Horrocks EJ, Thin N, Thaha MA, Taylor SJC, Norton C, Knowles CH. Systematic review of tibial nerve stimulation to treat faecal incontinence. Br J Surg. 2014;101:457–68.CrossRef Horrocks EJ, Thin N, Thaha MA, Taylor SJC, Norton C, Knowles CH. Systematic review of tibial nerve stimulation to treat faecal incontinence. Br J Surg. 2014;101:457–68.CrossRef
140.
go back to reference Richter HE, Dunivan G, Brown HW, Andy U, Dyer KY, Rardin C, et al. A 12-month clinical durability of effectiveness and safety evaluation of a vaginal bowel control system for the nonsurgical treatment of fecal incontinence. Female Pelvic Med Reconstr Surg. 2019;25:113–9. CrossRef Richter HE, Dunivan G, Brown HW, Andy U, Dyer KY, Rardin C, et al. A 12-month clinical durability of effectiveness and safety evaluation of a vaginal bowel control system for the nonsurgical treatment of fecal incontinence. Female Pelvic Med Reconstr Surg. 2019;25:113–9. CrossRef
141.
go back to reference Lukacz ES, Segall MM, Wexner SD. Evaluation of an anal insert device for the conservative management of fecal incontinence. Dis Colon Rectum. 2015;58:892–8.CrossRef Lukacz ES, Segall MM, Wexner SD. Evaluation of an anal insert device for the conservative management of fecal incontinence. Dis Colon Rectum. 2015;58:892–8.CrossRef
142.
go back to reference Graf W, Mellgren A, Matzel KE, Hull T, Johansson C, Bernstein M. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. The Lancet Elsevier BV. 2011;377:997–1003. Graf W, Mellgren A, Matzel KE, Hull T, Johansson C, Bernstein M. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. The Lancet Elsevier BV. 2011;377:997–1003.
143.
go back to reference Dehli T, Stordahl A, Vatten LJ, Romundstad PR, Mevik K, Sahlin Y, et al. Sphincter training or anal injections of dextranomer for treatment of anal incontinence: a randomized trial. Scand J Gastroenterol. 2013;48:302–10.CrossRef Dehli T, Stordahl A, Vatten LJ, Romundstad PR, Mevik K, Sahlin Y, et al. Sphincter training or anal injections of dextranomer for treatment of anal incontinence: a randomized trial. Scand J Gastroenterol. 2013;48:302–10.CrossRef
144.
go back to reference Lamblin G, Bouvier P, Damon H, Chabert P, Moret S, Chene G, et al. Long-term outcome after overlapping anterior anal sphincter repair for fecal incontinence. Int J Colorectal Dis. 2014;29:1377–83.CrossRef Lamblin G, Bouvier P, Damon H, Chabert P, Moret S, Chene G, et al. Long-term outcome after overlapping anterior anal sphincter repair for fecal incontinence. Int J Colorectal Dis. 2014;29:1377–83.CrossRef
145.
go back to reference Barbosa M, Glavind-Kristensen M, Moller Soerensen M, Christensen P. Secondary sphincter repair for anal incontinence following obstetric sphincter injury: functional outcome and quality of life at 18 years of follow-up. Colorectal Dis. 2020;22:71–9.CrossRef Barbosa M, Glavind-Kristensen M, Moller Soerensen M, Christensen P. Secondary sphincter repair for anal incontinence following obstetric sphincter injury: functional outcome and quality of life at 18 years of follow-up. Colorectal Dis. 2020;22:71–9.CrossRef
146.
go back to reference Lamblin G, Bouvier P, Damon H, Chabert P, Moret S, Chene G, et al. Long-term outcome after overlapping anterior anal sphincter repair for fecal incontinence. Lamblin G, Bouvier P, Damon H, Chabert P, Moret S, Chene G, et al. Long-term outcome after overlapping anterior anal sphincter repair for fecal incontinence.
Metadata
Title
Constipation and Fecal Incontinence in the Elderly
Authors
Benjamin I. Richter, MD
Anthony F. Skryd, MD
Scott M. Smukalla, MD
Publication date
27-09-2022
Publisher
Springer US
Published in
Current Treatment Options in Gastroenterology / Issue 4/2022
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-022-00401-1

Other articles of this Issue 4/2022

Current Treatment Options in Gastroenterology 4/2022 Go to the issue

Nutrition and Obesity (O Pickett-Blakely, Section Editor)

Revisiting Dietary Approaches in the Management of Chronic Pancreatitis

Geriatrics (A Faye and S Katz, Section Editors)

Evaluation of Diarrhea in Older Adults

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine